{
  "page_number": 29,
  "text": " \n \n24 \n \nReferences: \n1. Robinson JL, Freire D, Bialy L. Treatment strategies for cerebrospinal shunt infections: a \nsystematic review of observational studies. BMJ Open. 2020 Dec 10;10(12): e038978. doi: \n10.1136/bmjopen-2020-038978. PMID: 33303443; PMCID: PMC7733168. \n2. James HE, Bradley JS. Management of complicated shunt infections: a clinical report. J \nNeurosurg Pediatr. 2008 Mar;1(3):223-8. doi: 10.3171/PED/2008/1/3/223. PMID: 18352767. \n3. Eljaaly K. Dose and duration of intraventricular antibiotic therapy in meningitis. Clin Microbiol \nInfect. 2016 Sep;22(9):817. doi: 10.1016/j.cmi.2016.05.019. Epub 2016 May 30. PMID: \n27256064. \n4. Lewin JJ 3rd, Cook AM, Gonzales C, Merola D, Neyens R, Peppard WJ, Brophy GM, Kurczewski \nL, Giarratano M, Makii J, Rowe AS, Tesoro EP, Zaniewski A, Clark S, Ziai WC. Current Practices \nof Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results \nfrom a Multicenter Retrospective Cohort Study. Neurocrit Care. 2019 Jun; 30(3):609-616. doi: \n10.1007/s12028-018-0647-0. PMID: 30446934. \n \n2.5 Healthcare Associated Ventriculitis  \nType of Infection \nFirst Line (with Dosage and \nDuration) \nAlternative (with \ndosage and \nDuration) \nComments \nComplicated \n(Meningitis-Post- \nneurosurgery or \nPenetrating head \ntrauma or with \nbasilar skull \nfractures) \nMeropenem 2g IV q8h \n+ \nVancomycin 25 mg/kg IV stat \nfollowed by 15mg/kg q 8-12h  \n+ \nIf local antibiograms of healthcare \nassociated ventriculitis are \nsuggestive of high incidence of \ncarbapenem resistant Gram-\nnegative bacteria; then add cover \nfor carbapenem resistant \norganisms (Inj Fosfomycin 4g IV \nq6h or Inj Polymyxin B 15lacs IV \nstat and 7.5lacs IU BD) \nDuration of treatment:  14 -21 days \n \nHealthcare \nassociated \nVentriculitis and \nmeningitis \nmaybe a \nsequelae of \ninfections \noccurring in the \nproximal part of \nCSF shunts. \nFor common etiological agents of Healthcare Associated Ventriculitis, see Annexure B.2.5 \nAdditional Information:  \n• \nMay need intra ventricular antimicrobial therapy in severe cases. \n• \nFactors which increase the risk of post neuro-surgical infections:  \nCSF leak, CSF drainage, prolonged duration of surgery (> 4 hours), venous sinus surgery, \nimplantation of foreign materials, posterior approach to spinal surgery, diabetes, tobacco \nsmoking, previous neuro-surgeries, hair shaving in ventriculo-peritoneal shunt placement. \n• \nGuidance on the microbiological specimens to be submitted to the laboratory when shunt \ninfections are suspected is tabulated below: \n \n",
  "tables": [
    {
      "headers": [
        "Type of Infection First Line (with Dosage and Alternatvie (with Comments\nDuration) dosage and\nDuration)",
        "Col1",
        "Col2",
        "Col3"
      ],
      "rows": [
        [
          "Complicated\n(Meningitis-Post-\nneurosurgery or\nPenetrating head\ntrauma or with\nbasilar skull\nfractures)",
          "Meropenem 2g IV q8h\n+\nVancomycin 25 mg/kg IV stat\nfollowed by 15mg/kg q 8-12h\n+\nIf local antibiograms of healthcare\nassociated ventriculitis are\nsuggestvie of high incidence of\ncarbapenem resistant Gram-\nnegative bacteria; then add cover\nfor carbapenem resistant\norganisms (Inj Fosfomycin 4g IV\nq6h or Inj Polymyxin B 15lacs IV\nstat and 7.5lacs IU BD)\nDuration of treatment: 14 -21 days",
          "",
          "Healthcare\nassociated\nVentriculitis and\nmeningitsi\nmaybe a\nsequelae of\ninfectoi ns\noccurring in the\nproximal part of\nCSF shunts."
        ]
      ],
      "bbox": [
        72.18400319417317,
        330.72199096679685,
        539.9399820963541,
        573.507958984375
      ],
      "table_number": 0,
      "extraction_method": "standard"
    }
  ],
  "italic_text": [
    "BMJ Open.",
    "Neurosurg Pediatr.",
    "Clin Microbiol",
    "Infect.",
    "Neurocrit Care.",
    "Healthcare Associated Ventriculitis"
  ],
  "dimensions": {
    "width": 595.3200073242188,
    "height": 841.9199829101562
  }
}